

Isa Mambetsariev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8561080/publications.pdf>

Version: 2024-02-01

43
papers

692
citations

687363

13
h-index

610901

24
g-index

44
all docs

44
docs citations

44
times ranked

1075
citing authors

#	ARTICLE	IF	CITATIONS
1	Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Journal of Clinical Medicine</i> , 2022, 11, 1429.	2.4	12
2	Evaluation of Omics-Based Strategies for the Management of Advanced Lung Cancer. <i>JCO Oncology Practice</i> , 2021, 17, e257-e265.	2.9	8
3	Progressive Neurologic Changes in a Patient With Metastatic Non-Small-Cell Lung Cancer: Cancer Effects or a Secondary Diagnosis?. <i>JCO Oncology Practice</i> , 2021, 17, 52-53.	2.9	0
4	The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC). <i>Cell Reports Medicine</i> , 2021, 2, 100186.	6.5	90
5	Co-stimulatory and co-inhibitory immune markers in solid tumors with MET alterations. <i>Future Science OA</i> , 2021, 7, FSO662.	1.9	1
6	Predicting Survival Duration With MRI Radiomics of Brain Metastases From Non-small Cell Lung Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 621088.	2.8	23
7	Molecular and Clinical Features of Hospital Admissions in Patients with Thoracic Malignancies on Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 2653.	3.7	2
8	Evaluation of Somatic Mutations in Solid Metastatic Pan-Cancer Patients. <i>Cancers</i> , 2021, 13, 2776.	3.7	9
9	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
10	Protein Phosphatase 2A as a Therapeutic Target in Small Cell Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 1820-1835.	4.1	9
11	Elevated Eosinophil Count Following Pembrolizumab Treatment for Non-Small Cell Lung Cancer. <i>Cureus</i> , 2021, 13, e16266.	0.5	4
12	Therapeutic Potential of Olaparib in Combination With Pembrolizumab in a Young Patient With a Maternally Inherited BRCA2 Germline Variant: A Research Report. <i>Clinical Lung Cancer</i> , 2021, 22, e703-e707.	2.6	5
13	The Mitochondrion as an Emerging Therapeutic Target in Cancer. <i>Trends in Molecular Medicine</i> , 2020, 26, 119-134.	6.7	121
14	Activation of EPHA2-ROBO1 Heterodimer by SLIT2 Attenuates Non-canonical Signaling and Proliferation in Squamous Cell Carcinomas. <i>IScience</i> , 2020, 23, 101692.	4.1	9
15	A Non-genetic Mechanism Involving the Integrin $\alpha 24$ /Paxillin Axis Contributes to Chemoresistance in Lung Cancer. <i>IScience</i> , 2020, 23, 101496.	4.1	27
16	Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence. <i>Journal of Thoracic Disease</i> , 2020, 12, 5096-5103.	1.4	0
17	Role of immunotherapy and co-mutations on KRAS-mutant non-small cell lung cancer survival. <i>Journal of Thoracic Disease</i> , 2020, 12, 5086-5095.	1.4	29
18	Differentiating Peripherally-Located Small Cell Lung Cancer From Non-small Cell Lung Cancer Using a CT Radiomic Approach. <i>Frontiers in Oncology</i> , 2020, 10, 593.	2.8	25

#	ARTICLE	IF	CITATIONS
19	Non-Small Cell Lung Cancer from Genomics to Therapeutics: A Framework for Community Practice Integration to Arrive at Personalized Therapy Strategies. <i>Journal of Clinical Medicine</i> , 2020, 9, 1870.	2.4	16
20	Association of molecular characteristics with survival in advanced non-small cell lung cancer patients treated with checkpoint inhibitors. <i>Lung Cancer</i> , 2020, 146, 174-181.	2.0	8
21	Radiomic prediction of mutation status based on MR imaging of lung cancer brain metastases. <i>Magnetic Resonance Imaging</i> , 2020, 69, 49-56.	1.8	34
22	Complex Oncological Decision-Making Utilizing Fast-and-Frugal Trees in a Community Settingâ€”Role of Academic and Hybrid Modeling. <i>Journal of Clinical Medicine</i> , 2020, 9, 1884.	2.4	5
23	MET receptor in oncology: From biomarker to therapeutic target. <i>Advances in Cancer Research</i> , 2020, 147, 259-301.	5.0	20
24	Precision medicine and actionable alterations in lung cancer: A single institution experience. <i>PLoS ONE</i> , 2020, 15, e0228188.	2.5	7
25	Prolonged survival and response to tepotinib in a non-small-cell lung cancer patient with brain metastases harboring MET exon 14 mutation: a research report. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a005785.	1.2	8
26	Effects of selected deubiquitinating enzyme inhibitors on the proliferation and motility of lung cancer and mesothelioma cell lines. <i>International Journal of Oncology</i> , 2020, 57, 80-86.	3.3	1
27	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
28	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
29	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
30	Precision medicine and actionable alterations in lung cancer: A single institution experience. , 2020, 15, e0228188.		0
31	Small Cell Lung Cancer Therapeutic Responses Through Fractal Measurements: From Radiology to Mitochondrial Biology. <i>Journal of Clinical Medicine</i> , 2019, 8, 1038.	2.4	8
32	Monitoring and Determining Mitochondrial Network Parameters in Live Lung Cancer Cells. <i>Journal of Clinical Medicine</i> , 2019, 8, 1723.	2.4	5
33	Phenotypic Switching of Na ⁺ -ve T Cells to Immune-Suppressive Treg-Like Cells by Mutant KRAS. <i>Journal of Clinical Medicine</i> , 2019, 8, 1726.	2.4	26
34	EPHA2 mutations with oncogenic characteristics in squamous cell lung cancer and malignant pleural mesothelioma. <i>Oncogenesis</i> , 2019, 8, 49.	4.9	17
35	The brigatinib experience: a new generation of therapy for ALK-positive non-small-cell lung cancer. <i>Future Oncology</i> , 2018, 14, 1897-1908.	2.4	5
36	Modeling small cell lung cancer (SCLC) biology through deterministic and stochastic mathematical models. <i>Oncotarget</i> , 2018, 9, 26226-26242.	1.8	14

#	ARTICLE	IF	CITATIONS
37	Effective osimertinib treatment in a patient with discordant T790M mutation detection between liquid biopsy and tissue biopsy. <i>BMC Cancer</i> , 2018, 18, 314.	2.6	6
38	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 19793-19806.	1.8	34
39	Heuristic value-based framework for lung cancer decision-making. <i>Oncotarget</i> , 2018, 9, 29877-29891.	1.8	5
40	Differential Response of MET inhibition by Glesatinib (MGCD265) and Sitravatinib (MGCD516) in Non-small Cell Lung Cancer and Malignant Mesothelioma. <i>FASEB Journal</i> , 2018, 32, 835.9.	0.5	0
41	Value-Based Medicine and Integration of Tumor Biology. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2017, 37, 833-840.	3.8	7
42	Genomic mutation-driven metastatic breast cancer therapy: a single center experience. <i>Oncotarget</i> , 2017, 8, 26414-26423.	1.8	12
43	Post-crizotinib management of effective ceritinib therapy in a patient with ALK-positive non-small cell lung cancer. <i>BMC Cancer</i> , 2016, 16, 568.	2.6	1